# US 2022/0031606 A1 · System and method for prostrate treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031606 A1
- Document ID: US20220031606A1
- Status: Published application
- Kind: A1
- Application number: 17/092,079
- Filed: 2020-11-06
- Published: 2022-02-03
- Earliest claimed: 2019-11-07
- Assignees: Resurge Therapeutics, Inc.
- Applicants: Resurge Therapeutics, Inc.
- Inventors: Olof Mikael TROLLSAS; John J. STANKUS; Shahram Shawn GHOLAMI
- Web page: https://patentgrep.com/patent/US20220031606A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61B 8/085: {for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00)
- A61P 13/08: of the prostate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.

## Claims

### Claim 1

A system for treatment of benign prostatic hyperplasia tissue, comprising:
a sustained release formulation (SRF) comprising a cytostatic or cytotoxic drug, and
an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the SRF to the target tissue of the prostate.

### Claim 2 (depends on 1)

The system of claim 1, wherein the SRF is adapted to release the drug into the prostate over at least 14 days from being injected into the prostate, or over a 30 to 90 day period, or over a 90 to 180 day period.

### Claim 3 (depends on 1)

The system of claim 1, wherein the composition includes a solvent and the sustained release formulation.

### Claim 4 (depends on 1)

The system of claim 1, wherein the cytostatic drug consists of rapamycin, sirolimus, everolimus, temsirolimus, or zotarolimus.

### Claim 5 (depends on 1)

The system of claim 1, where the cytotoxic drug comprises paclitaxel.

### Claim 6 (depends on 1)

The system of claim 1, wherein the composition is an injectable solution and the sustained release formulation is formed into one or more of, or any of combination of microparticles, nanoparticles, rods, or a gel when the sustained release formulation comes into contact with the prostate.

### Claim 7 (depends on 1)

The system of claim 1, where the sustained release formulation is bioabsorbable and comprises a glycolide-based copolymer; optionally poly(lactide-co-glycolide).

### Claim 8 (depends on 1)

The system of claim 1, where the applicator comprises a needle for delivery of the composition by a transurethral, transrectal or transperineal access.

### Claim 9 (depends on 1)

The system of claim 1, wherein the system further includes an ultrasound device for locating a target in the prostate.

### Claim 10

A system for treatment of benign prostatic hyperplasia tissue, comprising:
a sustained release formulation comprising an alpha blocker, and/or a 5-alpha reductase inhibitor, and
an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate.

### Claim 11 (depends on 1)

The system of claim 1, wherein the composition further comprising an anti-inflammatory, alpha blocker, or a 5-alpha reductase inhibitor.

### Claim 12 (depends on 1)

The system of claim 1, wherein the composition comprises a bioabsorbable polymer at a concentration of 20-80%, 25-75%, 40-60% by wt. of the bioabsorbable polymer, 80-20%, 75-25%, 60-40%, by wt. of the solvent and 0.5%-30% by wt. drug; 1%-20% by wt. of drug, or 1%-5% by wt. of drug.

### Claim 13 (depends on 1)

The system of claim 1, wherein the drug has a release rate of no more than 10% to 75% over the first month, 25% to 95% over the first three months, and/or 50% to 100% over the first six months.

### Claim 14 (depends on 1)

The system of claim 1, wherein the drug has a release rate of between 5% to 50% during the first 24 hours from injecting the composition into the prostate.

### Claim 15 (depends on 1)

The system of claim 1, wherein the composition comprises a bioabsorbable polymer and the inherent viscosity of the polymer is between 0.2-1.0 dL/g, 0.2-0.6 dL/g, or 0.2 to 0.4 dL/g or 0.2 to 0.3 dL/g and the ratio of DL-lactide to glycolide is from 50/50 up to 90/10, 95/5, or 85/15.

### Claim 16 (depends on 1)

The system of claim 1, wherein the cytostatic or cytotoxic drug is 0.1 up to 10% wt. or up 20-30% wt. of the sustained release formulation.

### Claim 17 (depends on 1)

The system of claim 1, wherein the solvent is water soluble and non-toxic, and the composition comprises a polymer that is soluble in the solvent.

### Claim 18 (depends on 1)

The system of claim 1, wherein the solvent is water soluble or not water soluble, non-toxic, and/or the cytostatic or cytotoxic drug is soluble in in the solvent.

### Claim 19 (depends on 1)

The system of claim 1, wherein the solvent comprises N-methyl-pyrrolidone.

### Claim 20 (depends on 1)

A method of treatment using the system of claim 1, comprising:
injecting the composition into the prostate.
